Cocaine affinity decreased by mutations of aromatic residue phenylalanine 105 in the transmembrane domain 2 of dopamine transporter

Molecular Pharmacology

Volumn 63, Issue 3, 2003, Pages 653-658

  Wu, Xiaohong ^a,b   Gu, Howard H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Molecular Staging Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; COCAINE; DOPAMINE TRANSPORTER; GLUTAMINE; ISOLEUCINE; LEUCINE; MEMBRANE PROTEIN; METHIONINE; PHENYLALANINE; PROTEIN TM2; SERINE; THREONINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING KINETICS; COCAINE DEPENDENCE; DOPAMINE RELEASE; DROSOPHILA MELANOGASTER; DRUG ACTIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE CONSTRUCT; GENE MUTATION; MAMMAL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; RESIDUE ANALYSIS; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TRANSPORT KINETICS;

ANIMALS; COCAINE; DNA, COMPLEMENTARY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DROSOPHILA MELANOGASTER; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; NERVE TISSUE PROTEINS; PHENYLALANINE; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

EID: 0037334617     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.3.653     Document Type: Article

References (37)

1. Amara SG and Arriza JL (1993) Neurotransmitter transporters: three distinct gene families. Curr Opin Neurobiol 3:337-344.
2. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
3. Barker EL, Perlman MA, Adkins EM, Houlihan WJ, Pristupa ZB, Niznik HB, and Blakely RD (1998) High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem 273:19459-19468.
4. Barr LC, Goodman WK, Price LH, McDougle CJ, and Charney DS (1992) The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry 53 (Suppl):17-28.
5. Blakely RD, Clark JA, Rudnick G, and Amara SG (1991) Vaccinia-T7 RNA polymerase expression system: evaluation for the expression cloning of plasma membrane transporters. Anal Biochem 194:302-308.
6. Boyer WF and Feighner JP (1992) An overview of paroxetine. J Clin Psychiatry 53 (Suppl):3-6.
7. Buck KJ and Amara SG (1995) Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol Pharmacol 48:1030-1037.
8. Chen N, Vaughan RA, and Reith ME (2001) The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J Neurochem 77:1116-1127.
9. Fong TM, Yu H, and Strader CD (1992) Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96, 345 and RP67580. J Biol Chem 267:25668-25671.
10. Giros B and Caron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14:43-49.
11. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, and Caron MG (1994) Delineation of discrete domains for substrate, cocaine and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporter. J Biol Chem 269:15985-15988.
12. Goodnick PJ (1991) Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol Bull 27:513-519.
13. Gu H, Wall SC, and Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics and ion dependence. J Biol Chem 269:7124-7130.
14. Gu HH, Ahn J, Caplan MJ, Blakely RD, Levey AI, and Rudnick G (1996) Cell-specific sorting of biogenic amine transporters expressed in epithelial cells. J Biol Chem 271:18100-18106.
15. Guastella J, Nelson N, Nelson H, Czyzyk L, Keynan S, Miedel MC, Davidson N, Lester HA, and Kanner BI (1990) Cloning and expression of a rat brain GABA transporter. Science (Wash DC) 249:1303-1306.
16. Hall JM, Caulfield MP, Watson SP, and Guard S (1993) Receptor subtypes or species homologues: relevance to drug discovery. Trends Pharmacol Sci 14:376-383.
17. Iversen LL (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 41:571-591.
18. Kanner BI and Schuldiner S (1987) Mechanism of transport and storage of neurotransmitters. CRC Crit Rev Biochem 22:1-38.
19. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, and Uhl GR (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89:7782-7785.
20. Klein RG (1995) The role of methylphenidate in psychiatry. Arch Gen Psychiatry 52:429-433.
21. Koe BK (1990) Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 51 (Suppl B):13-17.
22. Kozak M (1991) Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem 266:19867-19870.
23. Lee SH, Chang MY, Lee KH, Park BS, Lee YS, and Chin HR (2000) Importance of valine at position 152 for the substrate transport and 2β-carbomethoxy-3β-(4-fluorophenyl)tropane binding of dopamine transporter. Mol Pharmacol 57:883-889.
24. Lin Z, Itokawa M, and Uhl GR (2000) Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition and expression. FASEB J 14:715-728.
25. Lin Z and Uhl GR (2002) Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol 61:885-891.
26. Lin Z, Wang W, Kopajtic T, Revay RS, and Uhl GR (1999) Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol 56:434-447.
27. Nelson RM and Long GL (1989) A general method of site-specific mutagenesis using a modification of the Thermus aquaticus polymerase chain reaction. Anal Biochem 180:147-151.
28. Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, and Ashkenazi A (1992) A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature (Lond) 360:161-163.
29. Pacholczyk T, Blakely RD, and Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature (Lond) 350: 350-354.
30. Porzgen P, Park SK, Hirsh J, Sonders MS, and Amara SG (2001) The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines. Mol Pharmacol 59:83-95.
31. Reith ME, Berfield JL, Wang LC, Ferrer JV, and Javitch JA (2001) The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276:29012-29018.
32. Ritz MC and Kuhar MJ (1993) Psychostimulant drugs and a dopamine hypothesis regarding addiction: update on recent research. Biochem Soc Symp 59:51-64.
33. Ritz MC, Lamb RJ, Goldberg SR, and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Wash DC) 237:1219-1223.
34. Rudnick G and Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249-263.
35. Seeman P and Madras BK (1998) Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 3:386-396.
36. Smith BH, Pelham WE, Gnagy E, and Yudell RS (1998) Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J Am Acad Child Adolesc Psychiatry 37:314-321.
37. Wu XH and Gu HH (1999) Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 233:163-170.